Vontobel Holding
AVTX icon

Vontobel Holding’s Avalo Therapeutics AVTX Stock Holding History

Vontobel Holding’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34
Closed -$320K – 1163
2021
Q2 		$320K Buy
34
+17
+100% +$142K ﹤0.01% 896
2021
Q1 		$145K Buy
17
+6
+55% +$56.7K ﹤0.01% 934
2020
Q4 		$87K Buy
+11
New +$76.4K ﹤0.01% 936

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vontobel Holding's AVTX Position: Q3 2021 in Review

Vontobel Holding sold out of Avalo Therapeutics (AVTX) in Q3 2021, closing a stake of 34 shares — an estimated $320K sold.

Vontobel Holding first reported a position in AVTX in Q4 2020 and held it in 3 quarters. The position peaked at $320K in Q2 2021. 71 funds tracked by Wall St. Rank hold AVTX as of Q3 2021.

  • Vontobel Holding reported no remaining Avalo Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vontobel Holding sold 34 Avalo Therapeutics shares in Q3 2021, an estimated $320K.
  • Vontobel Holding first reported a position in Avalo Therapeutics in Q4 2020 and held it in 3 quarters.
  • Vontobel Holding's Avalo Therapeutics position peaked at $320K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2021.

Based on Vontobel Holding's 13F filing for Q3 2021, filed 29 Oct 2021.